LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 6 of 497
Next
>>
>
126 to 150 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Dovitinib	0.04	uM	LJP5	3	E24	72	hr	1097	3581	3769	0.9500	0.9295
BT-20	Enzastaurin	0.04	uM	LJP5	1	D18	72	hr	1097	3729	3769	0.9893	0.9848
BT-20	Enzastaurin	0.04	uM	LJP5	2	D18	72	hr	1097	4053	3769	1.0752	1.1061
BT-20	Enzastaurin	0.04	uM	LJP5	3	D18	72	hr	1097	4031	3769	1.0694	1.0978
BT-20	Erlotinib	0.04	uM	LJP5	1	M24	72	hr	1097	3122	3769	0.8282	0.7577
BT-20	Erlotinib	0.04	uM	LJP5	2	M24	72	hr	1097	3202	3769	0.8494	0.7876
BT-20	Erlotinib	0.04	uM	LJP5	3	M24	72	hr	1097	3808	3769	1.0102	1.0144
BT-20	Foretinib	0.04	uM	LJP5	1	H12	72	hr	1097	3945	3769	1.0465	1.0657
BT-20	Foretinib	0.04	uM	LJP5	2	H12	72	hr	1097	3950	3769	1.0479	1.0675
BT-20	Foretinib	0.04	uM	LJP5	3	H12	72	hr	1097	4326	3769	1.1476	1.2082
BT-20	R406	0.04	uM	LJP6	1	C18	72	hr	1097	3634	3769	0.9640	0.9493
BT-20	R406	0.04	uM	LJP6	2	C18	72	hr	1097	3540	3769	0.9391	0.9141
BT-20	R406	0.04	uM	LJP6	3	C18	72	hr	1097	3174	3769	0.8420	0.7771
BT-20	Pictilisib	0.04	uM	LJP6	1	D24	72	hr	1097	2650	3769	0.7030	0.5811
BT-20	Pictilisib	0.04	uM	LJP6	2	D24	72	hr	1097	2604	3769	0.6908	0.5638
BT-20	Pictilisib	0.04	uM	LJP6	3	D24	72	hr	1097	2976	3769	0.7895	0.7031
BT-20	Gefitinib	0.04	uM	LJP6	1	N12	72	hr	1097	3552	3769	0.9423	0.9186
BT-20	Gefitinib	0.04	uM	LJP6	2	N12	72	hr	1097	3468	3769	0.9200	0.8872
BT-20	Gefitinib	0.04	uM	LJP6	3	N12	72	hr	1097	3549	3769	0.9415	0.9175
BT-20	Geldanamycin	0.04	uM	LJP5	1	O06	72	hr	1097	1378	3769	0.3656	0.1051
BT-20	Geldanamycin	0.04	uM	LJP5	2	O06	72	hr	1097	1835	3769	0.4868	0.2761
BT-20	Geldanamycin	0.04	uM	LJP5	3	O06	72	hr	1097	1909	3769	0.5064	0.3038
BT-20	Geldanamycin	0.04	uM	LJP6	1	O06	72	hr	1097	1234	3769	0.3274	0.0512
BT-20	Geldanamycin	0.04	uM	LJP6	2	O06	72	hr	1097	1261	3769	0.3345	0.0613
BT-20	Geldanamycin	0.04	uM	LJP6	3	O06	72	hr	1097	1345	3769	0.3568	0.0927

|<
<<
Previous
Page 6 of 497
Next
>>
>
126 to 150 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)